TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05932394

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Projection of Visual Material on Postoperative Delirium in Patients Undergoing Cardiac Surgery
Description: Patients are randomized into two groups (control group and intervention group). Initially, all patients are administered the Mini-Mental State Examination scale (MMSE) to assess their initial cognitive state and their sociodemographic and anthropometric data.~In the intervention group, patients and/or companions are asked to provide visual material, which could consist of photographs of loved ones and/or places known to the patient. 30 minutes after the extubation of the patients, the CAM-ICU scale is administered.~In the control group, after the surgical intervention and 30 minutes after the patient's extubation the CAM-ICU scale is administered.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the usual unit treatment
Description: CAM-ICU scale is administered to the Control group. No visual material is used.
Study: NCT05663476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non Surgical Periodontal Therapy
Description: Scaling and root planing using scalers and periodontal curettes will be done

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non Surgical Periodontal Therapy
Description: Scaling and root planing using scalers and periodontal curettes will be done
Study: NCT04968665

Intervention type: DIAGNOSTIC_TEST
Intervention: gait testing, functional MRI
Description: diagnostic tests including the gait testing and functional MRI
Study: NCT05289492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS884448
Description: EOS884448 will be administered in arm A,B and C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS884448
Description: EOS884448 will be administered in arm A,B and C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS884448
Description: EOS884448 will be administered in arm A,B and C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Iberdomide will be administered in arm B and C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Iberdomide will be administered in arm B and C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered in arm C
Study: NCT06490614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine in superficial cervical plexus block
Description: While the patient is in the supine position, the head will be turned to the opposite side of the surgical incision, and a line extending from the mastoid process to the clavicular head of the sternomastoid muscle will be marked. Aseptic preparation of this area will be done, and then the block needle will be inserted at the midpoint of this line with injection of bupivacaine 0.25%, dexmedetomidine 1 μg/kg (precedex 100mcg/ml), and adrenaline 1:200,000 in a total volume of 10ml normal saline in the above, below, and middle directions subcutaneously, creating a sausage-shaped swelling. The sensory block will be assessed with ice chips in the dermatome corresponding to the block, which included the skin of the neck, upper chest, shoulder, and ear, until the completion of the sensory blockade.
Study: NCT04928885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wits Workout Program
Description: 12 week, one hour per week multi-modal, interactive training.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group that receives intervention after the study
Description: The control group will not receive the intervention during study period but will take baseline, 3 mos and 6 mos surveys. They will complete the workshop after the study period is over.
Study: NCT06032559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MORE
Description: MORE plus TAU

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMP
Description: SMP plus TAU

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: TAU only
Study: NCT04894838

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal gastric bypass
Description: Distal gastric bypass, revisonal surgery after failed RYGB
Study: NCT05663476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non Surgical Periodontal Therapy
Description: Scaling and root planing using scalers and periodontal curettes will be done
Study: NCT04989088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProComp5 Infiniti System w/BioGraph Infiniti Software
Description: Left theta/beta NF training in combination with right beta/theta NF training in temporo-parietal regions, for 40 minutes (with a 20-minute break period)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ProComp5 Infiniti System w/recorded videos
Description: Sham NF training using pre-recorded videos, for 40 minutes (with a 20-minute break period)
Study: NCT05668949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by IV (vein)
Study: NCT06505421

Intervention type: BEHAVIORAL
Intervention: Resistance training
Description: Eccentric resistance training and tradional resistance training
Study: NCT05812196

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung function test
Description: Spirometry to assess lung volumes, forced oscillations to measure respiratory mechanics, whole body plethysmography to assess static lung volumes and airway resistance, lung diffusion capacity measurements.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung function test
Description: Spirometry to assess lung volumes, forced oscillations to measure respiratory mechanics, whole body plethysmography to assess static lung volumes and airway resistance, lung diffusion capacity measurements.

Intervention type: BIOLOGICAL
Intervention: COVID infection
Description: Verified COVID-19 infection.
Study: NCT05056545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: C4 Intervention
Description: C4 Intervention, is an innovative form of Post Partum Family Planning (PPFP). PPFP methods include: the copper intrauterine device, hormonal implant, tubal ligation, and (after 6 weeks post-partum in breastfeeding women) Depo-Provera and oral contraceptive pills. These are provided as current, standard of care in Rwanda, are procured by the government, and administered by trained nurses and doctors.~The C4 training will occur at the 4 pilot facilities. Training will include a 2-day didactic session covering PPFP provision, follow-up, use of the C4 counseling flipchart; mock counseling sessions; and PPIUD and PP implant insertion and removal trainings. The study team will train government clinic staff in family planning, ANC, L\&D, and IV to promote C4 at the selected facilities. 'Happy Clients' will be recruited from women who received promotions and selected PPFP to join a clinic-based PPFP promotions team. Women interested in PPFP will be referred to the facility by their CHW.
Study: NCT06786741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AER for Stronger Communities
Description: 3 week rapid intervention aimed at reducing stress.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 3 week short video program (control)
Study: NCT06792318

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FAPI PET-CT
Description: FAPI PET-CT imaging protocol:~Single dose 68Ga/18F-FAPI (2 MBq/kg)~Two imaging sessions:~First: 10 and 30 minutes post-injection Second: 60 and 80 minutes post-injection Ultra-low dose CT for attenuation correction and anatomical localization
Study: NCT06792136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-1110
Description: ONO-1110 tablets once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-1110
Description: ONO-1110 tablets once a day
Study: NCT06153069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short-course regimen
Description: During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, \>70kg 2000mg daily; ethambutol ≤50kg 750mg daily, \>50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (0 or 9 weeks based on the radiological manifestations), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard regimen
Description: During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, \>70kg 2000mg daily; ethambutol ≤50kg 750mg daily, \>50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (18 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally.
Study: NCT06792136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once daily
Study: NCT06792370

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ready-to-use therapeutic food (for children with MAM)
Description: Each child with MAM will be supplemented with RUTF for a maximum of 12 weeks. He/she will be followed subsequently up to 24 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ready-to-use supplementary food
Description: Each child with MAM will be supplemented with RUSF for a maximum of 12 weeks. He/she will be followed subsequently up to 24 weeks post recovery

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready to Use Therapeutic Food - Reduced dose 1
Description: Each child with SAM will be treated with a reduced dose for a maximum of 12 weeks : dose of 150-185 kcal/kg/day of RUTF until programmatic recovery. He/she will be followed subsequently up to 24 weeks post recovery.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ready to Use Therapeutic Food - Standard dose
Description: Each child with SAM will be treated with a standard dose (according to the national protocol for the integrated management of acute malnutrition in Burkina Faso) for a maximum of 12 weeks. He/she will be followed subsequently up to 24 weeks post recovery.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready to Use Therapeutic Food - Reduced dose 2
Description: Each child with SAM will be treated with a reduced dose for a maximum of 12 weeks : dose of 150-185 kcal/kg/day of RUTF until the child is no longer severely malnourished and does not have nutritional oedema then 100-130 kcal/kg/day of RUTF until programmatic recovery. He/she will be followed subsequently up to 24 weeks post recovery.
Study: NCT06792500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerol Tributyrate
Description: Participants will be administered orally three times a day enteric hard capsules containing 500 mg of glycerol tributyrate with an 8-ounce glass of water on an empty stomach: morning, noon, and evening during the dose-escalation phase. Each MELAS participant will undergo a six-month dose escalation phase of glycerol tributyrate, starting at a dose of 1,000 mg (tid) per day during the first month followed by a monthly increase of 500 mg (tid) per dose of glycerol tributyrate with the maximal oral dose of glycerol tributyrate 3,500 mg (tid) per dose at the end of six-month-long dose escalation phase. Once the participant-specific fixed maximum tolerated dose (MTD) is determined, MELAS participants will take an oral administration of this MTD three times a day during the 12-month-long clinical phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerol Tributyrate
Description: Participants will be administered orally three times a day enteric hard capsules containing 500 mg of glycerol tributyrate with an 8-ounce glass of water on an empty stomach: morning, noon, and evening during the dose-escalation phase. Each MELAS participant will undergo a six-month dose escalation phase of glycerol tributyrate, starting at a dose of 1,000 mg (tid) per day during the first month followed by a monthly increase of 500 mg (tid) per dose of glycerol tributyrate with the maximal oral dose of glycerol tributyrate 3,500 mg (tid) per dose at the end of six-month-long dose escalation phase. Once the participant-specific fixed maximum tolerated dose (MTD) is determined, MELAS participants will take an oral administration of this MTD three times a day during the 12-month-long clinical phase.
Study: NCT06790459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UlfTens (Ultra-low-frequencies Transcutaneous electrical nervous stimulation)
Description: ULFTENS device will be administered in the experimental group for 15 minutes
Study: NCT06791759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The course on technology use in nursing
Description: Students attended in the course technology use in nursing. The course consisted of 2 hours per week over 14 weeks. The course aims to provide students with an understanding of fundamental technological developments in nursing, highlighting the importance and impact of technology in nursing education and practice.Theoretical lessons were delivered by two nurse educators over 8 weeks through PowerPoint presentations and interactive discussions. For the remaining five weeks, students were given some assignments to increase their interaction with digital technological tools. Three assignments were planned for each of the students. In this context, microsoft teams, canva, microsoft powerpoint, kahoot, mentimeter, quizlet, ed-puzzle, capcut, mobile health applications, google classroom, discord and artificial intelligence applications were used for assignments.
Study: NCT06792552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0505 for injection
Description: Every 21 days is one cycle. Multiple dose levels of SIM0505 will be explored in dose escalation, and determine the maximum tolerated dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0505 for injection
Description: Every 21 days is one cycle. 2-3 dose levels of SIM0505 will be explored in dose optimization, and determine the recommended dose (RD) of SIM0505 and evaluate the preliminary anti-tumor activity of SIM0505
Study: NCT06790888

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ripertamab/Eltrombopag
Description: Ripertamab, a novel anti-CD20 monoclonal antibody, in combination with Eltrombopag . Ripertamab is administered intravenously at a dose of 375 mg/m² BSA on Day 1 . If the participant remains in remission at the 3-month mark, an additional intravenous dose of 375 mg/m² Ripertamab is administered. Eltrombopag are given orally at an initial dose of 2.5 mg once daily, with dosage adjustments made every two weeks based on platelet count response, for a total treatment duration of up to Day 28.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eltrombopag
Description: Eltrombopag as a single therapy. Eltrombopag is a thrombopoietin receptor agonist given orally at an initial dose of 2.5 mg once daily, with dosage adjustments made every two weeks based on platelet count response, for a total treatment duration of up to Day 28.
Study: NCT06790693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Participants will receive oral inavolisib once daily (QD).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive oral placebo QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDK4/6i
Description: Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CDK4/6i
Description: Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Participants will receive oral letrozole QD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole
Description: Participants will receive oral letrozole QD.
Study: NCT06791928

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer distribution of self testking kits
Description: Participants will be given a demonstration and instructions on how to use self-test kits (written and pictorial instructions in Luganda) and provided with ten serialized kits (five HIVST and five syphilis self-testing) to distribute to eligible social and sexual network members. Peers effective at reaching infrequent and non-testers will be asked to distribute an additional three to five test kits. Each peer will receive an IRB-approved $5 for each kit distributed and accounted for as in prior studies. (62). Respondents will be compensated for each successful recruitment, and SNS recruiting will continue until the sample size of 200 is attained. Each peer will receive a REC-approved transport facilitation of $30 per month since most MSM who have never tested are hard to trace. Control group peers will only distribute invitation letters for fast-track HIV/syphilis at the study clinic to minimize contamination (i.e., use of the intervention by control group participants).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer distribution of self testking kits
Description: Participants will be given a demonstration and instructions on how to use self-test kits (written and pictorial instructions in Luganda) and provided with ten serialized kits (five HIVST and five syphilis self-testing) to distribute to eligible social and sexual network members. Peers effective at reaching infrequent and non-testers will be asked to distribute an additional three to five test kits. Each peer will receive an IRB-approved $5 for each kit distributed and accounted for as in prior studies. (62). Respondents will be compensated for each successful recruitment, and SNS recruiting will continue until the sample size of 200 is attained. Each peer will receive a REC-approved transport facilitation of $30 per month since most MSM who have never tested are hard to trace. Control group peers will only distribute invitation letters for fast-track HIV/syphilis at the study clinic to minimize contamination (i.e., use of the intervention by control group participants).
Study: NCT06791083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: 150mg/m2 , IH， d1；Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: 5 mg ，po，QD，d1-d14；Q3W
Study: NCT06792305

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Starting by anterior ring fixation in vertical shear pelvic ring injuries
Description: The procedure will involve addressing the pelvic ring anteriorly with open reduction and internal fixation (ORIF) of the pubic rami and symphysis pubis by using a single 3.5 mm recon plate. The goal isto achieve anatomical reduction and stable fixation to restore the integrity of the pelvic ring. Fixation of the posterior ring will be achieved using a single sacroiliac screw in S1. The goal of posterior fixation is to achieve stability and alignment of the posterior pelvic structures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Starting by posterior ring fixation in vertical shear pelvic ring injuries
Description: the procedure will involve fixation of the posterior ring which will be achieved by using a single sacroiliac screw in S1. Then open reduction and internal fixation (ORIF) of the pubic rami and symphysis pubis by using a single 3.5 mm recon plate.
Study: NCT06790277

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex Border Sacrum dressings
Description: Both types of intervention will be available in the operating room. Patient will be examined by head nurse of wound management team after the operation then at day 3- and 7-days post operation. The dressing should be removed after 7 days post operation or if there is any clinical indication for removal. If a patient is discharged before 7 days post operation for any reason the head nurse of wound management team will examine the patient before discharge. Follow up will be for maximum 7 days post operation for each subject. Any patient will be unable to continue the study because of death or change in the care setting will be excluded from the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyurethane foams (Pink Pad)
Description: Both types of intervention will be available in the operating room. Patient will be examined by head nurse of wound management team after the operation then at day 3- and 7-days post operation. The dressing should be removed after 7 days post operation or if there is any clinical indication for removal. If a patient is discharged before 7 days post operation for any reason the head nurse of wound management team will examine the patient before discharge. Follow up will be for maximum 7 days post operation for each subject. Any patient will be unable to continue the study because of death or change in the care setting will be excluded from the study.
Study: NCT06791577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboxytherapy
Description: Application of the intervention (CO2 Lift) in the area according to the protocol schedule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of the placebo (Vaseline) in the area according to the protocol schedule
Study: NCT06791551

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active RIPC and tDCS
Description: Preoperative use of a therapeutic device with sleeves fixed on the upper side of both arms, compressing the bilateral brachial arteries to 200mmHg for 5 minutes, resting for 5 minutes, repeating 5 times, recorded as 1 time, training once in the morning and afternoon each day, and continuing treatment for at least 3 days; Administer transcranial electrical stimulation, 2mA, 30min, for 3 days;

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: received sham treatment with the same appearance instrument;
Study: NCT06790433

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibraject
Description: The needle was advanced into the tissue until it was estimated to be over the root apex while remaining parallel to the tooth's long axis. The Vibraject was activated after aspiration to deposit the solution slowly at approximately 50 seconds. Following cartridge deposition, the operator adjusted the participant to an upright seated position

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dentapen
Description: The needle was advanced into the tissue until it was estimated to be over the root apex while remaining parallel to the tooth's long axis (needle placement). The Dentapen was activated after aspiration to deposit the solution at a medium rate (1 mL/60 s) using the ramp-up mode. Following cartridge deposition, the operator adjusted the participant to an upright seated position